# KLOW Peptide: A Clinical Reference on the Four-Arm Research Blend

> KLOW peptide composes four research arms — KPV, GHK-Cu, BPC-157 and TB-500 — into one vial. A calm clinical reference on the blend rationale, each component's literature, and the honest evidence gap.

A calm clinical reference on KPV, GHK-Cu, BPC-157 and TB-500 — what the component studies actually measured, where the evidence is solid, and where the honest gaps are.

## In plain English

KLOW peptide is a research blend that puts four peptides — KPV, GHK-Cu, BPC-157, and TB-500 — into a single vial. Each of the four has its own published research record in areas like tissue repair, inflammation, and matrix remodeling. The idea behind combining them is that each one works on a different part of the same repair process: one damps down inflammation, one supports the structural tissue (called the extracellular matrix), one encourages new blood-vessel growth, and one helps cells move and close wounds. The typical research vial contains 80 mg total, with GHK-Cu as the largest portion at 50 mg and the other three at 10 mg each.

Here is the important caveat: no one has ever tested the four-peptide KLOW blend itself in a controlled study. Every claim about how the blend performs is an extrapolation from single-component research. That is an honest gap, and this site records it plainly. None of the four compounds is FDA-approved for human use. TB-500 is on the WADA prohibited list for sport. What people report from research use — and what to watch out for — is on the [KLOW effects](/effects) page.

## What is KLOW peptide

KLOW peptide is a co-formulated research blend of four chemically distinct peptides: KPV (Lys-Pro-Val, a tripeptide and the C-terminal fragment of alpha-MSH, the melanocyte-stimulating hormone), GHK-Cu (the copper(II) complex of Gly-His-Lys, also called Copper Tripeptide-1), BPC-157 (a 15-amino-acid synthetic peptide derived from a gastric-juice protein sequence), and TB-500 (a synthetic heptapeptide corresponding to the actin-binding motif of the native protein thymosin beta-4). The four are co-dissolved in a single lyophilized vial — they remain four separate molecules, not a single chemical entity.

The canonical research-vial composition is 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg [1]. GHK-Cu dominates by mass at roughly 62.5% of the vial. No FDA-approved or pharmacopeial KLOW combination product exists; the blend is supplied strictly as a research-chemical co-formulation. No single CAS number, UNII, or PubChem CID covers the mixture.

## KLOW peptide blend: the four-arm rationale

The combination rationale rests on the observation that the four components address largely non-overlapping nodes of the tissue-repair signaling network. KPV suppresses innate-immune transcription: it inhibits NF-kappaB (a transcription factor — the cellular switch that turns on inflammatory genes) nuclear import in epithelial and immune cells and reduces TNF-alpha, IL-6 and IL-1beta in human intestinal-epithelial-cell models [3]. GHK-Cu acts at the transcriptome level — it modulates expression of approximately 31% of human protein-coding genes at a 50%-or-greater change threshold in cultured fibroblasts, with the strongest signals on extracellular matrix remodeling, antioxidant defense and DNA repair, and supplies copper for lysyl oxidase (the enzyme responsible for collagen crosslinking) [4, 5]. BPC-157 drives the VEGFR2/PI3K/Akt/eNOS angiogenic pathway — promoting new blood-vessel growth — and upregulates the growth-hormone receptor in tendon fibroblasts, accelerating tendon healing in rodent transection models [2]. TB-500 (with the strongest evidence for full-length native thymosin beta-4) sequesters G-actin (monomeric actin, the cell's building block for movement) via its LKKTET motif to accelerate cell migration and re-epithelialization — increasing wound closure by 42% at four days and 61% at seven days in rat full-thickness wound models [1].

The plain summary: one arm controls inflammation, one remodels the structural scaffold, one builds new vessels, one moves the cells that close the wound. Each step is required for full tissue repair; these four arms address each in turn. That is the rationale for a KLOW blend.

**Critical caveat — no blend data exists.** The four-arm composition rationale is mechanistic extrapolation, not a tested hypothesis. No controlled in-vivo or human study has compared the four-peptide KLOW blend against monotherapy, any subset, or placebo. A pharmacokinetic mismatch is also inherent: the two tripeptides (KPV and GHK-Cu) clear far faster than the larger BPC-157, and the TB-500 fragment behaves differently from native thymosin beta-4, so a single co-formulated dose cannot hold all four at matched exposures simultaneously. These gaps are recorded throughout this site.

## KLOW blend: constituent breakdown

**KPV (anti-inflammatory arm) — 10 mg.** Molecular weight 342.44 Da. CAS 67727-97-3. KPV is transported into inflamed intestinal epithelial cells via PepT1 (SLC15A1), a di/tripeptide transporter that is upregulated in inflamed gut tissue, with a Km of approximately 160 micromolar [3]. At nanomolar concentrations in cell culture, KPV inhibits NF-kappaB and MAP-kinase inflammatory signaling and reduces pro-inflammatory cytokine secretion. In DSS- and TNBS-induced mouse colitis models, oral KPV reduced disease severity [3].

**GHK-Cu (matrix remodeling arm) — 50 mg.** Molecular weight 402.92 Da. CAS 89030-95-5. First isolated from human plasma by Loren Pickart in 1973; endogenous plasma levels decline from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 [4]. Stimulates collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin synthesis; in topical clinical studies increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid [4]. At the genomic level, GHK modulates approximately 31% of human genes at a 50%-or-greater change threshold [5].

**BPC-157 (angiogenic arm) — 10 mg.** Molecular weight 1419.53 Da. CAS 137525-51-0. Sequence: GEPPPGKPADDAGLV. Derived from a partial sequence of a protein identified in human gastric juice. Accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic and macroscopic measures in a peer-reviewed model; stimulated tendocyte outgrowth in vitro [2]. A 2025 first-in-human IV safety pilot reported no adverse events at doses up to 20 mg in two healthy adults [6].

**TB-500 (cytoskeletal / wound-closure arm) — 10 mg.** Molecular weight 889.02 Da. Sequence: Ac-LKKTETQ. The LKKTET motif sequesters G-actin, linked to cell migration and re-epithelialization. Most foundational efficacy data are for full-length native thymosin beta-4 (43 amino acids), not the TB-500 heptapeptide fragment — a distinction the literature requires. In a rat full-thickness wound model, thymosin beta-4 increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline [1]. Note: TB-500/thymosin beta-4 is on the WADA Prohibited List (S2) and is banned at all times in sport.

## KLOW: status and open questions

None of the four components is FDA-approved for human use. BPC-157 was placed by the FDA in category 2 of the 503A bulk-substances review. The blend itself has no regulatory classification, no pharmacopeial standard, and no approved indication anywhere. It is a research-chemical co-formulation.

A 2026 Sports Medicine systematic review of approved and unapproved peptide therapies for musculoskeletal conditions concluded that many unapproved peptides show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [7]. That assessment applies directly to KLOW: extensive rodent literature across three of the four components, thin human data, and no blend-level study of any kind.

The [component research](/research) page sets out the key studies. The [KLOW effects](/effects) page records what the research-use community reports — clearly labeled as anecdotal — alongside the cited safety cautions. The [dosage research](/dosage) page documents the doses administered in component studies without recommending any human dose.

---

A calm clinical reference on the component literature — four peptides set out arm by arm, each finding kept to its own study.